Kimberly Stegmaier
- Molecular Biology top 2%
- Hematology top 0.5%
- Oncology top 2%
- Cancer Research top 2%
- Public Health, Environmental and Occupational Health top 2%
- Co-authors
- Kenneth N. RossTodd R. GolubAndrew L. KungGabriela AlexeGiovanni RotiJustin LambAlexandre PuissantWilliam C. Hahn
- Topics
- Protein Degradation and Inhibitors (43 papers)Acute Myeloid Leukemia Research (33 papers)Acute Lymphoblastic Leukemia research (21 papers)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Kimberly Stegmaier
128 papers receiving 5.3k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Molecular Biology 3.6k
- Hematology 1.2k
- Oncology 1.0k
- Cancer Research 757
- Public Health, Environmental and Occupational Health 713
Countries citing papers authored by Kimberly Stegmaier
This map shows the geographic impact of Kimberly Stegmaier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly Stegmaier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly Stegmaier more than expected).
Fields of papers citing papers by Kimberly Stegmaier
This network shows the impact of papers produced by Kimberly Stegmaier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly Stegmaier. The network helps show where Kimberly Stegmaier may publish in the future.
Co-authorship network of co-authors of Kimberly Stegmaier
This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly Stegmaier. A scholar is included among the top collaborators of Kimberly Stegmaier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly Stegmaier. Kimberly Stegmaier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 4 | |
| 4 | 27 | |
| 5 | 4 | |
| 6 | 21 | |
| 7 | 24 | |
| 8 | 8 | |
| 9 | 12 | |
| 10 | 9 | |
| 11 | 23 | |
| 12 | 12 | |
| 13 | 28 | |
| 14 | 26 | |
| 15 | 145 | |
| 16 | 43 | |
| 17 | 46 | |
| 18 | 81 | |
| 19 | 42 | |
| 20 | Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibitionbreakdown → | 457 |
About Kimberly Stegmaier
Kimberly Stegmaier is a scholar working on Hematology, Molecular Biology and Neurology, having authored 135 papers that have together received 5.4k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (43 papers), Acute Myeloid Leukemia Research (33 papers) and Acute Lymphoblastic Leukemia research (21 papers). The work is most often cited by research in Hematology (1.2k citations), Molecular Biology (3.6k citations) and Cancer Research (757 citations). Kimberly Stegmaier has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Kenneth N. Ross, Todd R. Golub, Andrew L. Kung, Gabriela Alexe, Giovanni Roti, Justin Lamb, Alexandre Puissant, William C. Hahn, James E. Bradner and TR Golub. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.